Endometrial Cancer Clinical Trial
Verified date | February 2016 |
Source | Far Eastern Memorial Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Taiwan: Institutional Review Board |
Study type | Observational |
Endometrial cancer is the second common gynecologic malignancy in Taiwan. The prevalence has
been overcome the epithelial ovarian cancer because of the change of life style to western
style recently. Most patients with endometrial cancer are stage I & II, the most histology
is still "endometrioid adenocarcinoma" (type I endometrial cancer). In statistics, advanced
stage (FIGO stage III and IV) is approximately 16% of all cases.
Most patients has good outcome of endometrial cancer because their surgical stage is
belonged to "early stage". However, the recurrence, distant metastases and mortality are
high if the diseases is confirmed to be advanced stage. The adjuvant therapies after
staging/debulking operation are systemic chemotherapy and whole pelvic radiation therapy/
brachytherapy. Whether the adjuvant therapy can cure the disease of not is still
controversial.
Because of the rarity of the advanced endometrial cancer, varies adjuvant therapeutic
modalities, eg. chemotherapy only, pelvic radiation therapy only, combination of
chemotherapy and radiation therapy or sequential "sandwich" therapy were ever used for such
group patients in each medical center. But the case number is insufficient and limited to
show the survival or progression free benefit during the statistics. Besides, the surgical
procedures and adjuvant therapy for early endometrial cancer is still remained to be
determined. The investigators are also interested to analyze the factors affecting their
survival.
The investigators will perform a retrospective study to review the data of patients with
endometrial cancer in Department of Obstetrics & Gynecology in Far Eastern Memorial
Hospital.
Status | Completed |
Enrollment | 100 |
Est. completion date | May 2016 |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 99 Years |
Eligibility |
Inclusion Criteria: 1. Time interval: from 1991 to date. 2. Comprehensive surgical staging or debulking procedure. 3. All female patients with endometrial cancer who underwent surgery for endometrial cancer at Far Eastern Memorial Hospital. Exclusion Criteria: 1. Not comprehensive staging/debulking procedure. 2. Patients who died of postoperative complications within 30 days after surgery were excluded from the survival analysis. |
Observational Model: Case-Only, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
Taiwan | Far Eastern Memorial Hospital | Banqiao | New Taipei |
Lead Sponsor | Collaborator |
---|---|
Far Eastern Memorial Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Factors affecting overall survival and disease-free survival of endometrial cancer | 20 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05796518 -
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
|
N/A | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06463028 -
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT03820024 -
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
|
N/A | |
Active, not recruiting |
NCT05082025 -
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
|
Phase 2 | |
Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
Completed |
NCT05378152 -
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
|
N/A | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Recruiting |
NCT04569773 -
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Not yet recruiting |
NCT06073184 -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
|
Phase 2 | |
Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
Not yet recruiting |
NCT05998798 -
Revealing Engagement Patterns Among Endometrial Cancer Patients
|
||
Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
Completed |
NCT02413606 -
ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More?
|
N/A |